G17DT Immunogen
Also known as: Anti-gastrin vaccine, G17DT, Gastrimmune, Gastrin‑17 diphtheria toxoid, Gastrin‑17 vaccine, PAS (polyclonal antibody stimulator)
Source G17DT Immunogen at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
G17DT is a gastrin‑17 peptide chemically conjugated to diphtheria toxoid (DT) used as an immunogenic cancer vaccine to elicit antibodies against gastrin‑17, aiming to inhibit growth of gastrin‑dependent gastric cancers.
Mechanism of Action
Induces anti‑gastrin‑17 antibodies by presenting gastrin‑17 linked to diphtheria toxoid, neutralising gastrin‑mediated proliferative signaling in gastric mucosa and tumors.
Routes of Administration
Goals & Uses
- Inhibition of tumor angiogenesisOncology / MechanisticLow
- Treatment of colorectal cancerOncologyLow
- Prevention of gastric cancer recurrenceOncologyModerate
- Treatment of pancreatic cancerOncologyModerate
- Treatment of gastric adenocarcinomaOncologyModerate
- Post-surgical adjuvant therapyOncologyLow
- Treatment of gastric cancerOncologyModerate
Contraindications
- Hypersensitivity to diphtheria toxoidAllergyHigh
- Known hypersensitivity to diphtheria toxoidAllergy / ImmunologyHigh
- Active autoimmune disordersImmunologyModerate
- Severe immunodeficiencyImmunologyModerate
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Severe immunosuppressionImmunologyModerate
Adverse Effects
- Flu-like symptomsSystemic/ImmunologicalCommon
- Hypersensitivity / allergic reactionsImmunologicRare
- Injection site reactionsLocalCommon
- Gastrointestinal disturbancesGastrointestinalUncommon
- Hypersensitivity reactionImmunologicRare
- Reduced gastric acid secretionGastrointestinal / PharmacodynamicUncommon
- Injection site erythemaLocalCommonRedness at the injection site
- Flu‑like systemic symptomsSystemicCommon
Drug Interactions
- Chemotherapy agentsModerate
- Proton pump inhibitors / H2 blockersLow
- Immunosuppressive agents (e.g., corticosteroids, biologics)Moderate
- Immunosuppressive agents (e.g., corticosteroids, methotrexate)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Patients with active severe infectionsInfectious DiseaseRelative
- Pediatric patientsAgeRelative
- Pediatrics (<18 y)AgeAbsolute
- Elderly patients with poor immune functionAge / ImmunologicRelative
Regulatory Status
- European UnionInvestigationalClinical trial sponsor; not authorized by EMA.
- United StatesInvestigationalInvestigational New Drug (IND) application filed; no FDA approval.
- United KingdomInvestigationalUnder clinical investigation; not licensed by MHRA.
Investigational vaccine; has undergone Phase II/III clinical trials for gastric cancer but has not received regulatory approval in major jurisdictions.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is G17DT Immunogen?
G17DT is a gastrin‑17 peptide chemically conjugated to diphtheria toxoid (DT) used as an immunogenic cancer vaccine to elicit antibodies against gastrin‑17, aiming to inhibit growth of gastrin‑dependent gastric cancers.
What is G17DT Immunogen used for?
G17DT Immunogen is educationally associated with: Inhibition of tumor angiogenesis, Treatment of colorectal cancer, Prevention of gastric cancer recurrence, Treatment of pancreatic cancer, Treatment of gastric adenocarcinoma, Post-surgical adjuvant therapy, Treatment of gastric cancer. Educational only — not medical advice.
How is G17DT Immunogen administered?
Recorded routes of administration: Intramuscular, Subcutaneous.
What are the potential side effects of G17DT Immunogen?
Reported adverse effects include: Flu-like symptoms, Hypersensitivity / allergic reactions, Injection site reactions, Gastrointestinal disturbances, Hypersensitivity reaction, Reduced gastric acid secretion, Injection site erythema, Flu‑like systemic symptoms. This list is not exhaustive — consult a qualified clinician.
Who should avoid G17DT Immunogen?
Recorded contraindications: Hypersensitivity to diphtheria toxoid, Known hypersensitivity to diphtheria toxoid, Active autoimmune disorders, Severe immunodeficiency, Pregnancy, Severe immunosuppression. Consult a qualified clinician before use.